Eurofound's EU PolicyWatch collates information on the responses of government and social partners to the COVID-19 crisis, the war in Ukraine, rising inflation, as well as gathering examples of company practices aimed at mitigating the social and economic impacts.
Factsheet for measure NL-2020-27/2087 – Updated – measures in Netherlands
| Country | Netherlands , applies nationwide |
| Time period | Temporary, 01 July 2020 – 01 July 2024 |
| Context | COVID-19 |
| Type | Other initiatives or policies |
| Category |
Supporting businesses to stay afloat
– Access to finance |
| Author | Thomas de Winter (Panteia) and Eurofound |
| Measure added | 02 December 2021 (updated 02 March 2025) |
The Growth Facility is a measure that existed before the pandemic, it was set to close on 1 July 2020 as Invest-NL (a private investment company) would take-over this form of financing. However, due to the outbreak of COVID-19, the cabinet in the Netherlands decided that they would extend this measure to 1 July 2023. The reason behind the extension is to help to SMEs impacted during the COVID-19 economic crisis to still have the opportunity to acquire financing for their risk-bearing capital venture.
The strategy behind this measure is to provide a guarantee to financiers who give venture capital to SMEs. If a SME incurs a loss on their investment, they can recoup 50% of that loss. In this case, the government intends to cover the 50% loss incurred by the SME. The guarantee covers losses suffered as a result of the sale of stock, the writing off of a debt, or bankruptcy. The warranty is valid for a maximum of 12 years.
The Growth Facility is executed by the National Enterprise Agency (“RVO”). In terms of the application process, only financing facilities are eligible to apply for this scheme. In the case of entrepreneurs, it is possible to apply for a loan through one of the participating banks or private venture companies. The financier decides whether he will submit a request for a guarantee to RVO for the financing and whether he will ultimately grant the loan. The scheme does not apply to entrepreneurs directly.
The Growth Facility applies different maximum amounts: A bank can provide a guarantee financing up to a maximum of €5 million in the form of subordinated loans. Half of this amount can be brought under warranty. Risk-bearing capital (subordinated loans and/or share capital), provided by private equity firms, is subject to a maximum of €25 million. The guarantee amount is half of this. The government has agreed to adjust the amount of the guarantee in order to make the Growth Facility available to as many enterprises and financiers as feasible during the Corona crisis. Currently, this amount has being adjusted again from €25 million to €50 million.
The Cabinet has made a budget of €85 million per year available.
The following updates to this measure have been made after it came into effect.
| 13 November 2024 |
Extension until 1 July 2024 |
There is currently no data available on the use of measure.
| Workers | Businesses | Citizens |
|---|---|---|
| Does not apply to workers |
SMEs
|
Does not apply to citizens |
| Actors | Funding |
|---|---|
|
National government
|
National funds
|
Social partners' role in designing the measure and form of involvement:
| Trade unions | Employers' organisations | |
|---|---|---|
| Role | Unknown | Unknown |
| Form | Not applicable | Not applicable |
Social partners' role in the implementation, monitoring and assessment phase:
Unknown.
In a report by MKB-Nederland and VNO-NCO, stated this comment in relation to the Growth Facility scheme: “Subordinated loans are a form between debt and equity. These types of loans have a positive effect on the solvency and thus the financial ability of companies. As a result, they have a larger financial buffer, and it can be more attractive for banks and other investors to provide a loan."
Citation
Eurofound (2021), Growth Facility (GF): government guarantee on risk-bearing capital, measure NL-2020-27/2087 (measures in Netherlands), EU PolicyWatch, Dublin, https://static.eurofound.europa.eu/covid19db/cases/NL-2020-27_2087.html
Share
All publications are available on the EU PolicyWatch landing page .
Disclaimer: This information has not been subject to the full Eurofound evaluation, editorial and publication process.